Research graph
References from Inhaled Tobramycin Effectively Reduces FEV1 Decline in Cystic Fibrosis. An Instrumental Variables Analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Patient registry: 2011 annual report
2012 · External reference
Predictors of deterioration of lung function in cystic fibrosis
10.1002/ppul.10100 · 2002 · External reference
Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition
10.1002/ppul.2009 · 2001 · External reference
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
10.1002/ppul.10127 · 2002 · External reference
Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health
10.1164/rccm.200705-664oc · 2007 · External reference
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
10.1056/nejm199901073400104 · 1999 · External reference
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
10.1183/09031936.02.00248102 · 2002 · External reference
Improving evidence-based care in cystic fibrosis through quality improvement
10.1001/archpediatrics.2010.178 · 2010 · External reference
Crossing the quality chasm: a new health system for the 21st century
2001 · External reference
Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation
10.1097/00001648-200301000-00014 · 2003 · External reference
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution
10.1002/ppul.21521 · 2012 · External reference
Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables
10.1001/jama.1994.03520110039026 · 1994 · External reference
Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods
10.1001/jama.297.3.278 · 2007 · External reference
The central role of the propensity score in observational studies for causal effects
10.1093/biomet/70.1.41 · 1983 · External reference
Econometrics in outcomes research: the use of instrumental variables
10.1146/annurev.publhealth.19.1.17 · 1998 · External reference
Identification of causal effects using instrumental variables
10.1080/01621459.1996.10476902 · 1996 · External reference
Instruments for causal inference: an epidemiologist’s dream?
10.1097/01.ede.0000222409.00878.37 · 2006 · External reference
Does ambulatory process of care predict health-related quality of life outcomes for patients with chronic disease?
10.1111/j.1475-6773.2006.00604.x · 2007 · External reference
Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance
10.1016/j.jclinepi.2008.12.006 · 2009 · External reference
Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships
10.1016/j.jclinepi.2008.12.005 · 2009 · External reference
Effects of long-term tobramycin on lung function decline in children with cystic fibrosis
2011 · External reference
Lung function decline from adolescence to young adulthood in cystic fibrosis
10.1002/ppul.21526 · 2012 · External reference
Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients
10.1016/s1569-1993(02)00141-8 · 2003 · External reference
Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease
10.1002/ppul.20097 · 2004 · External reference
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
10.1378/chest.121.1.55 · 2002 · External reference
Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis
10.1016/j.jpeds.2007.03.006 · 2007 · External reference
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis
10.1164/rccm.200702-181oc · 2007 · External reference
Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis
10.1164/rccm.200802-327oc · 2008 · External reference
Semiparametric regression
10.1017/cbo9780511755453 · 2003 · External reference
Instrumental variables and inverse probability weighting for causal inference from longitudinal observational studies
10.1191/0962280204sm351ra · 2004 · External reference
Design issues for drug epidemiology
10.1046/j.1365-2125.2000.00289.x · 2000 · External reference
Predictors of mortality in adults with cystic fibrosis
10.1002/ppul.20619 · 2007 · External reference
Year-to-year changes in lung function in individuals with cystic fibrosis
10.1016/j.jcf.2010.04.002 · 2010 · External reference
Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable
10.1097/01.ede.0000193606.58671.c5 · 2006 · External reference
A national survey of pediatric critical care resources in the United States
10.1542/peds.2004-1920 · 2005 · External reference
Treatment effect estimates varied depending on the definition of the provider prescribing preference-based instrumental variables
10.1016/j.jclinepi.2011.06.012 · 2012 · External reference
Current issues in quality improvement in cystic fibrosis
10.1016/j.ccm.2007.02.013 · 2007 · External reference
Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review
10.1016/j.jada.2008.02.020 · 2008 · External reference
